C4 Therapeutics unveils 2025 milestones; cash runway extended into 2027

C4 Therapeutics, Inc.

Cash, cash equivalents and marketable securities as of Dec 31, 2024 expected to fund operations into 2027.
Cemsidomide Phase 1 dose escalation in multiple myeloma and NHL to complete in 2H 2025; next-phase studies to start early 2026.
CFT1946 monotherapy dose escalation in BRAF V600 solid tumors to complete 1H 2025; Phase 1 data in melanoma and CRC expected 2H 2025.
CFT8919 Phase 1 data from partner Betta in China will inform future development outside China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.